<DOC>
	<DOCNO>NCT00519792</DOCNO>
	<brief_summary>Omega DUROS® implantable drug delivery system design deliver omega interferon subcutaneously constant rate 90 day . This study perform evaluate safety antiviral effect omega interferon deliver Omega DUROS® device combination ribavirin subject chronic Hepatitis C genotype 1 .</brief_summary>
	<brief_title>Phase 1b Study Omega DUROS® Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic Hepatitis C HCV genotype 1 infection Relapse follow end treatment response treatment pegylated interferon ribavirin . Presence history nonHCV chronic liver disease Treatment interferon subsequent relapse pegylated interferonalpha ribavirin Decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Relapse</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
</DOC>